Gut,
a leading international journal from BMJ and BSG, publishes cutting-edge gastroenterology and hepatology research and reviews
Impact Factor: 31.795
Citescore: 40.1
All metrics >>
Latest Visual Abstract
Editor's Choice
Helicobacter pylori:
Helicobacter pylori promotes colorectal carcinogenesis by deregulating intestinal immunity and inducing a mucus-degrading microbiota signature7 June 2023
Recent advances in basic science:
It is better to light a candle than to curse the darkness: single-cell transcriptomics sheds new light on pancreas biology and disease5 May 2023
Gut microbiota:
Akkermansia muciniphila counteracts the deleterious effects of dietary emulsifiers on microbiota and host metabolism4 April 2023
Inflammatory bowel disease:
Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study7 March 2023
Most Read Articles
Guidelines:
British Society of Gastroenterology guidelines on the management of functional dyspepsia11 August 2022
Guidelines:
Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report11 August 2022
Inflammatory bowel disease:
Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study9 January 2023
Latest Articles
Recent advances in clinical practice:
Timing of energy intake and the therapeutic potential of intermittent fasting and time-restricted eating in NAFLD7 June 2023
Letter:
Hypophosphataemia following ferric carboxymaltose and ferric derisomaltose: case closed, but questions remain2 June 2023
Recent advances in basic science:
Emerging interleukin targets in the tumour microenvironment: implications for the treatment of gastrointestinal tumours31 May 2023
Altmetrics
Podcasts
Featured Video
Severity of gastric intestinal metaplasia predicts the risk of gastric cancer: a prospective multicentre cohort study (GCEP)
We suggest a risk-stratified approach and recommend that high-risk patients (OLGIM III–IV) have endoscopic surveillance in 2 years, intermediate-risk patients (OLGIM II) in 5 years.
Find out more